# Diploma Course on Research & Development of Products to Meet Public Health Needs

Organized by

Nagasaki University, Japan and Faculty of Allied Health Sciences, Thammasat University, Thailand in cooperation with

Graduate School of Pharmaceutical Science, The University of Tokyo, Japan,
Chulalongkorn University, Thailand,
China Second Military Medical University, China,
Universidad de Antioquia, Colombia

28 October – 9 November, 2013

**Objective:** To provide basic knowledge and skills of the different steps in the whole process of PRD to research scientists, post-graduate students, medical doctors involved in PRD, regulatory authorities, professionals.

**Output:** At the end of the course, the participants will be able to: 1. Describe the development activities related in the PRD process. 2.Integrate the various components needed for PRD and 3. Disseminate the knowledge to other scientists and institutions working in any aspect of PRD in order to work together

**Outcome:** Increase research activity on PRD in DEC (Disease Endemic Countries) institutions **Participants**: Research scientists, post-graduate students, medical doctors involved in PRD, regulatory authorities, professionals.

Research scientists/Professionals:

- (1) Diploma degree in science
- (2) Involved as a member of the team in any aspect of PRD
- (3) Good track record- work ethics and ability to work as a team/recommendation letter from supervisor
- (4) Conversant in English

Post-graduate students:

- (1) Accepted in the post-graduate program
- (2) Good track record- work ethics and ability to work as a team/recommendation letter from supervisor
- (3) Conversant in English

#### Medical doctors:

- (1) Degree in medicine
- (2) Involved as a member of the team in any aspect of PRD
- (3) Good track record- work ethics and ability to work as a team/recommendation letter from supervisor
- (4) Conversant in English

Regulatory authorities:

- (1) Diploma degree
- (2) Member of the regulatory in the country
- (3) Good track record- work ethics and ability to work as a team/recommendation letter from supervisor
- (4) Conversant in English

Course Language: English

**Course format:** This is 12 days course consisting of lectures, open discussions, group activity, site visit and practical exercises on specific activities.

#### Course Directors:

Professor Dr. Juntra Laothavorn

Institute of Tropical Medicine (NEKKEN)

Nagasaki University, Nagasaki, Japan

Email: <u>karbwangj@nagasaki-u.ac.jp</u>

Tel: +81-95-819-7285

Professor Dr. Kenji Hirayama

Institute of Tropical Medicine (NEKKEN)

Nagasaki University, Nagasaki, Japan

Email: hiraken@nagasaki-u.ac.jp

Tel: +81-95-819-7818

Professor Dr. Kesara Na-Bangchang

Director, Clinical Coordination and Training Center, Thammasat University

Faculty of Allied Health Sciences, Thammasat University

Email: kesaratmu@yahoo.com

Tel: +66-2-9869207

#### Venue:

Seminar Room No. 125, Institute of Tropical Medicine (NEKKEN), Nagasaki University (Sakamoto Campus)

#### Registration deadline: 15 October, 2013

(We also accept onsite registration however registration kit materials are not guaranteed)

#### **Administration Office**

The information should be sent to
Ms. Ikumi Frizt
secretary, Diploma Course Office,
Institute of Tropical Medicine, Nagasaki University
e-mail: <a href="mailto:fritz@nagasaki-u.ac.jp">fritz@nagasaki-u.ac.jp</a>

## **Module 1: Introduction**

Recognize the concept needs of PRD in medical and global view of health

0	cto	ber	28,	Mor	ıdav	(Day	1)
_			,				_,

09:30-09:45	Welcome address
	Professor Dr. Kenji Hirayama, Institute of Tropical Medicine
	(NEKKEN), Nagasaki University, Japan
09:45-10:00	Objective of the course and expectation, Pre-test
	Professor Dr. Kenji Hirayama, Institute of Tropical Medicine
	(NEKKEN), Nagasaki University, Japan
10:00-10:15	Break
10:15-11:15	Overview of product research and development and stakeholders
	Professor Dr. Juntra Karbwang-Laothavorn, Nagasaki
	University, Japan
11:15-12:15	Key medical and public health issues, and the need for new
	products
	Professor Dr. Kenji Hirayama, Institute of Tropical Medicine
	(NEKKEN) Nagasaki University, Japan
12:15-14:00	Lunch

# **Module 2: Drug Discovery and Development**

#### **Session 1: Discovery Phase**

Describe the pharmacological process for drug discovery. Identify the process to protect intellectual property.

14:00-14:30	History and overview of drug discovery process
	Dr. Nobuhiro Noro, GlaxoSmith Kline, K.K., Japan
14:30-15:00	The role of Genomics and bioinformatics
	Dr. Nobuhiro Noro, GlaxoSmith Kline, K.K., Japan
15:00-15:30	High throughput screening:
	Pre-requisite of HITS systems, Assay Development & Validation,
	Biochemical & Cell-based assay, Assay Readout & Detection
	Dr. Nobuhiro Noro, GlaxoSmith Kline, K.K., Japan
15:30-15:45	Break
15:45-16:15	The role of Chemistry in Drug Discovery:-Lead Identification,

-Lead Generation Libraries (Combinationial Chemistry, Computational Approaches), -Lead Optimization *Dr. Nobuhiro Noro, GlaxoSmith Kline, K.K., Japan* 

16:15-16:45 Pharmacokinetic Issues in Drug Discovery:

- Designs and Purposes of DMPK Profiles of Lead & Drug Candidates
- DMPK studies in Drug Discovery (Late lead identification & Early lead optimization, Mid lead optimization, Late lead optimization)
- Prediction of DMPK and PKPD Correlation
- Prediction of Toxicity

Dr. Nobuhiro Noro, GlaxoSmith Kline, K.K., Japan

#### **Session 2: Pre-clinical Development**

Describe the process of pharmacological development

16:45-17:45 Pharmaceutical Development and CMC

Professor Dr. Hitoshi Sasaki,

Nagasaki University Hospital, Japan

## October 29, Tuesday (Day 2)

09:00-09:45 The role of Pharmacology

- Pharmacological Evaluations (Selectivity screening, Pharmacological profiling, Testing in animal models of disease, Safety pharmacology)

- Examples

Professor Dr. Yoshimasa Tanaka, Nagasaki University, Japan

09:45-10:15 Biopharmaceuticals

- Development of Biopharmaceuticals
- Type of Biopharmaceuticals
- Issues Related to the use of Biopharmaceuticals (Antigenicity, Stability, Drug delivery)

Professor Dr. Kesara Na-Bangchang, Thammasat University,

**Thailand** 

10:15-10:30 Break

10:30-11:30 Drug Discovery in Academia

Professor Dr. Kesara Na-Bangchang, Thammasat University,

Thailand

11:30-12:30 Patents in Drug Discovery:

- Publication VS Patents

- Patent system

- Type of Patent

Professor Dr. Hiroshi Kato, Nihon University, Japan

12:30-13:30 Lunch

## **Session 2: Pre-clinical Development**

Describe the process of pharmacological development

12 20 14 00	$\sim$	•	T)	1 1	. 1	• ,	C	1	1 1
13:30-14:00	( )verv	/16W.	Pre-	clinical	study	requiments	tor	hiiman	clinical
13.30 11.00	O V CI	V 1 C V V .	110 1	cillicai	stuay	requiritions	101	munitum.	cillical

studies

Professor Dr. Kesara Na-Bangchang, Thammasat University,

**Thailand** 

14:00-15:00 Assessing of Drug Safety: the role of toxicology

- Objective and Type of Toxicology

- Exploratory Toxicology

- Regulatory Toxicology

- Toxicity Measures and Toxicity Test

Professor Dr. Kesara Na-Bangchang, Thammasat

University, Thailand

15:00-15:15 Break

15:15-16:15 Pharmacokinetics

Professor Dr. Kesara Na-Bangchang, Thammasat University,

Thailand

## October 30, Wednesday (Day 3)

### **Session 3: Clinical Development**

09:00-09:30 Overview of clinical development

	Professor Dr. Juntra Karbwang-Laothavorn, Nagasaki
	University, Japan
09:30-11:00	Investigational Phases of Clinical
	Research (I-IV) and Study Design
	Professor Dr. Juntra Karbwang-Laothavorn, Nagasaki
	University, Japan
11:00-11:15	Break
11:15-12:15	Regulatory Framework
	Dr. Shimokawa Masafumi, Coordination Division Office of
	Planning and Coordination Pharmaceuticals and Medical Devi
	ces Agency
12:15-13:30	Lunch
13:30-14:00	Clinical Development Plan
	Professor Dr. Juntra Karbwang-Laothavorn, Nagasaki
	University, Japan
14:00-14:30	Pharmacogenomics
	- Anticipated Benefits
	- Polymorphisms in Drug Targets
	- Polymorphisms in ADME
	- Pharmacogenomics Testing
	- Pharmacogenomics in Clinical Trials
	- Examples
	Dr.Shyh-Yuh Liou, Takeda Pharmaceutical Company Limited
	Head Office, Japan
14:30-15:00	Pharmacokinetics in Clinical Development
	Extrapolation from animal to human pharmacokinetics
	Dr.Shyh-Yuh Liou, Takeda Pharmaceutical Company Limited
	Head Office, Japan
15:00-15:15	Break

## **Session 4: Traditional Medicine**

Underline the importance of traditional medicine in PRD

15:15-16:10	Introduction of Traditional Medicine and Guidance on herbal
	medicine
	Professor Dr. Kiichiro Tsutani, The University of Tokyo, Japan
16:10-17:00	Regulation for traditional medicine development
	Dr. Ichiro Arai, Tsumura & Co., Japan
17:00-17:45	Rev and Exam 1 (Module 2)
	Professor Dr. Hirayama or Professor Dr. Kesara
	October 31, Thursday (Day 4)
10:00-17:00	Field Trip to Hisamitsu Pharmaceutical Co.,Inc
	Mr. Hiroyuki Hidaka, Hisamitsu Pharmaceutical Co.,Inc

# **Module 3: Vaccine Development**

## November 1, Friday (Day 5)

## **Session 1: Discovery**

Describe the principles of basic immunology. Describe the process of vaccine discovery

09:00-09:30	Historical overview of vaccine Discovery
	Professor Dr. Kenji Hirayama, Nagasaki University, Japan
09:30-10:30	Vaccines for infection control
	Professor Dr. Kenji Hirayama, Nagasaki University, Japan
10:30-10:45	Break
10:45-12:15	Vaccines for infection control
	Professor Dr. Kenji Hirayama, Nagasaki University, Japan
12:15-13:30	Lunch
13:30-14:30	Vaccine Platform Technology and Adjuvant Development
	Dr. Takeshi Arakawa, University of the Ryukyus, Japan

#### **Session 2: Pre-Clinical Development**

Describe the process of pre-clinical development of vaccine

14:30-15:00	CMC
	Dr. Takeshi Arakawa, University of the Ryukyus, Japan
15:00-15:15	Break
15:15-15:45	Immunogenicity and protect activity assessment

Dr. Takeshi Arakawa, University of the Ryukyus, Japan 15:45-16:30 Safety assessment:Toxicity test in animals: regional

complications, systemic toxicity

Dr. Takeshi Arakawa, University of the Ryukyus, Japan

## November 4, Monday (Day 6)

### **Session 3: Clinical Development**

Describe the process of vaccine clinical development

09:00-10:00	Assessment of pre-clinical information	
	TBD	
10:00-10:30	Clinical development plan	
	TBD	
10:30-10:45	Break	
10:45-11:45	Dose selection and regimen	
	TBD	
11:45-13:30	Lunch	
13:30-15:45	Case studies	
	Professor Dr. Kenji Hirayama, Nagasaki University, Japan	
15:45-16:00	Break	
16:00-17:00	Rev and Exam 3 (Module 3)	
	Professor Dr. Kenji Hirayama, Nagasaki University, Japan	

# **Module 4: Diagnostic Development**

# November 5, Tuesday (Day 7)

Describe the process of discovery and development of diagnostic tools

Discovery and development of diagnostic tools
Dr. Masato Sasaki, QIAGEN, Japan
Prototype production and assessment
Dr. Masato Sasaki, QIAGEN, Japan

10:30-10:45	Break
10:45-11:45	Scale-up, manufacture and control
	Dr. Masato Sasaki, QIAGEN, Japan
11:45-12:30	Development of kits
	Dr. Masato Sasaki, QIAGEN, Japan
12:30-13:45	Lunch
13:45-14:45	Quality assurance/quality control: evaluation of efficacy after
	application
	Dr. Masato Sasaki, QIAGEN, Japan
14:45-15:45	Clinical development: validate prototype, manufacture pilot lot,
	initiate clinical trial
	Dr. Masato Sasaki, QIAGEN, Japan
15:45-16:00	Break
16:00-16:30	Clinical development: Supply chain logistics and production,
	Statistical
	Dr. Masato Sasaki, QIAGEN, Japan
16:30-17:00	Rev and Exam 4 (Module 4)
	Professor Dr. Kenji Hirayama and Professor Dr.Kesara Na-
	Bangchang
	Professor Dr. Kenji Hirayama, Nagasaki University, Japan

# **Module 5: Good Clinical Practice**

# November 6, Wednesday (Day 8)

Describe the concepts of GCP, Recognise the principles of Ethics in research and the functions of Ethics Committee

09:00-09:30	Concept of Good Clinical Practice
	Professor Dr. Juntra Karbwang, Nagasaki University, Japan
09:30-10:30	Principles of Research Ethics and Ethics codes and Guidance
	Professor Dr. Juntra Karbwang, Nagasaki University, Japan
10:30-10:45	Break

10:45-11:45	Responsibilities: Sponsor, Monitors, audit, DSMB  Professor Dr. Juntra Karbwang, Nagasaki University, Japan
11:45-12:30	Responsibilities of EC
	Professor Dr. Juntra Karbwang, Nagasaki University, Japan
12:30-13:30	Lunch
13:30-16:00	Case studies
	Professor Dr. Juntra Karbwang, Nagasaki University, Japan
	Professor Dr. Kesara Na-Bangchang, Thammasat University,
	Thailand
16:00-16:30	Break
16:30-17:00	Review and Exam
	Professor Dr. Juntra Karbwang, Nagasaki University, Japan
	Professor Dr. Kesara Na-Bangchang, Thammasat University,
	Thailand

# **Module 6: Clinical Data Management**

# November 7, Thursday (Day 9)

Describe clinical data management processes, Describe how to write a good SOP for CDM

09:00-10:00	Overview, Protocol, CRF, SOPs
	Professor Dr. Kesara Na-Bangchang, Thammasat University
10:00-11:00	Data management process I
	Professor Dr. Kesara Na-Bangchang, Thammasat University,
	Thailand
11:00-11:15	Break
11:15-11:45	Data management process I (Demo)
	Professor Dr. Kesara Na-Bangchang, Thammasat University,
	Thailand
11:45-12:15	Data management process II
	Professor Dr. Kesara Na-Bangchang, Thammasat University,
	Thailand
12:15-13:15	Lunch
13:15-13:45	Data management II (Demo)
	Ms. Panida Kongjam, Thammasat University Clinical Data

	Management Center, Thailand
13:45-14:15	Data management process III
	Professor Dr. Kesara Na-Bangchang, Thammasat University,
	Thailand
14:15-15:15	Data management process III (Practice)
	Ms. Panida Kongjam, Thammasat University Clinical Data
	Management Center, Thailand
15:15-16:15	Statistical analysis and sample size estimation
	Professor Dr. Kesara Na-Bangchang, Thammasat University,
	Thailand
16:15-16:45	Rev and Exam 6 (Module 6)
	Professor Dr. Kesara Na-Bangchang, Thammasat University,
	Thailand

# **Module 7: Post-registration Activities**

# November 8, Friday (Day 10)

Describe post-registration activities for medicinal products

09:00-10:00	Overview
	Professor Chitr Sitthi-amorn, Chulalongkorn University,
	Bangkok, Thailand
10:00-11:00	How to solve Access to Medicines (ATM) problems in
	developing countries
	Professor Chitr Sitthi-amorn, Chulalongkorn University,
	Bangkok, Thailand
11:00-11:15	Break

11:15-12:15	Improving the quality of new products in health systems:
	International network of rational use of drugs
	Professor Chitr Sitthi-amorn, Chulalongkorn University,
	Bangkok, Thailand
12:15-13:15	Lunch
13:15-14:15	Post-marketing product vigilance
	Professor Chitr Sitthi-amorn, Chulalongkorn University,
	Bangkok, Thailand
14:15-15:15	Stakeholders to be involved in making product development
	work for the intended beneficiaries
	Professor Chitr Sitthi-amorn, Chulalongkorn University,
	Bangkok, Thailand
15:15-15:30	Break
15:30-16:30	Intellectual Property Rights Protection in Developing Countries
	Professor Hiroko Yamane, Teikyo University, Japan
16:30-17:00	Rev and Exam 2 (Module 7)
	Professor Dr. Kenji Hirayama, Nagasaki University, Japan

## November 9, Saturday (Day 11)

#### 9:00-11:00 FINAL EVALUATION. COURSE ASSESSMENT

Professor Dr. Kenji Hirayama, Nagasaki University, Japan Professor Dr. Juntra Karbwang, Nagasaki University, Japan, Course Director

#### 11:00-12:00 **CLOSING CEREMONY**

Professor Dr. Kenji Hirayama, Institute of Tropical Medicine (NEKKEN) Nagasaki University, Japan